Last Updated : September 23, 2023
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
|Brand Name||Generic Name||Therapeutic Area||Recommendation Type||Project Status||Date Submission Received||Date Recommendation Issued Sort descending|
|Breo Ellipta||fluticasone furoate/vilanterol||Asthma||Withdrawn|
|Mvasi||Bevacizumab||mCRC NSCLC Biosimilar||N/A||Complete|
|TBC||filgrastim||Prevention or treatment of neutropenia in various indications||Cancelled|
|Fulphila||pegfilgrastim||Febrile neutropenia in non-myeloid malignancies||N/A||Complete|
|Semglee||insulin glargine||Diabetes mellitus, Type 1 & 2||Withdrawn|